Watertown, MA, United States of America

Basel Karzoun

This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Eyepoint Pharmaceuticals, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Basel Karzoun: Innovator in Ocular Drug Delivery

Introduction

Basel Karzoun is an accomplished inventor based in Watertown, MA (US). He is known for his innovative contributions to the field of ocular drug delivery. His work focuses on developing advanced methods for delivering pharmaceutical ingredients directly to the eye.

Latest Patents

Karzoun holds a patent for a bioerodible ocular drug delivery insert and therapeutic method. This invention relates to implantable bioerodible inserts designed to deliver an active pharmaceutical ingredient to the eye. The patent also encompasses methods of treatment using these inserts, as well as the manufacturing processes involved in creating them. He has 1 patent to his name.

Career Highlights

Throughout his career, Karzoun has worked with notable companies in the pharmaceutical industry, including Eyepoint Pharmaceuticals, Inc. and Eye Point Ltd. His experience in these organizations has contributed significantly to his expertise in ocular drug delivery systems.

Collaborations

Karzoun has collaborated with professionals such as Dario Paggiarino and Michelle Howard-Sparks. These partnerships have enhanced his research and development efforts in the field.

Conclusion

Basel Karzoun is a pioneering inventor whose work in ocular drug delivery has the potential to improve therapeutic methods for eye care. His innovative patent and collaborations reflect his commitment to advancing medical technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…